Trial reportCNS neuroscience & therapeutics2026
Glycemic Status and Effect of Immediate Intensive Statin on Mild Ischemic Stroke: A Subgroup Analysis of the INSPIRES Trial.
Trial report in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aimsA subgroup analysis of the Intensive Statin and Antiplatelet Therapy for High-risk Intracranial or Extracranial Atherosclerosis (INSPIRES) trial to evaluate intensive statin effects in patients with ischemic stroke by glycemic status.
methodPatients were stratified into three subgroups based on glycemic status: without type 2 diabetes mellitus (T2DM), with newly diagnosed T2DM, with a history of T2DM. The primary outcomes included stroke and moderate-to-severe bleeding, whereas secondary outcomes comprised composite vascular events, poor functional outcomes, and any bleeding within 90 days.
resultsAmong 6100 patients, 4038 were without T2DM, 404 had a newly diagnosed T2DM, and 1658 had a history of T2DM. No significant risk reduction of stroke was observed with immediate versus delayed statin therapies across glycemic subgroups (p for interaction = 0.29). Compared to delayed-intensive statin, immediate-intensive statin treatment was associated with reduced risk of poor functional outcome in non-T2DM patients (adjusted relative risk 0.71, 95% CI 0.57-0.90; p = 0.004), but no benefit in those with newly diagnosed T2DM or those with a history of T2DM (p for interaction = 0.003). There was no glycemic status by treatment interaction for risk of bleeding or composite vascular event.
conclusionsPatients without T2DM derived greater benefit in functional outcomes from immediate-intensive statin after ischemic stroke than those with T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.